We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 535.00 | 521.00 | 524.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSLN
RNS Number : 8322B
Silence Therapeutics PLC
12 October 2020
Director Dealing
12 October 2020
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that, on the 8th and 9th October 2020, 9,750 Shares were purchased by Iain Ross, Chairman of the Company, through his self-invested personal pension (SIPP) at GBP4.10 per share, 1,250 Shares were purchased by David Lemus, Non-Executive Director of the Company, at GBP4.00 per share, 3,000 Shares were purchased by James Ede-Golightly, Non-Executive Director of the Company, at GBP4.09 per share, and 4,945 Shares were purchased by Dr. Giles Campion, Executive Director of the Company, at GBP4.04 per share.
Following this purchase, Iain Ross is interested in 54,443 ordinary shares (0.07%) of the issued share capital of the Company, David Lemus is interested in 6,876 ordinary shares (0.01%) of the issued share capital of the Company, James Ede-Golightly is interested in 3,000 ordinary shares (0.00%) of the issued share capital of the Company, and Dr. Giles Campion is interested in 14,945 ordinary shares (0.02%) of the issued share capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Hot Features
Premium
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Iain Ross
--------------------------- --------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position / status Chairman
--------------------------- --------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- --------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- --------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares of 5 pence each in Silence
the financial instrument, Therapeutics plc
type of instrument
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- --------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares in Silence
Therapeutics plc
--------------------------- --------------------------------------------
c) Prices(a) and volume(s) Price Volume
GBP4.10 9,750
-------
--------------------------- --------------------------------------------
d) Aggregated information
- Aggregated volume 9,750 Ordinary Shares
- Price GBP39,976.00
--------------------------- --------------------------------------------
e) Date of the transaction 8 October 2020
--------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--------------------------- --------------------------------------------
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name David Lemus
--------------------------- --------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position / status Non-Executive Director
--------------------------- --------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- --------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- --------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares of 5 pence each in Silence
the financial instrument, Therapeutics plc
type of instrument
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- --------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares in Silence
Therapeutics plc
--------------------------- --------------------------------------------
c) Prices(a) and volume(s) Price Volume
GBP4.00 1,250
-------
--------------------------- --------------------------------------------
d) Aggregated information
- Aggregated volume 1,250 Ordinary Shares
- Price GBP5,000.00
--------------------------- --------------------------------------------
e) Date of the transaction 9 October 2020
--------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--------------------------- --------------------------------------------
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name James Ede-Golightly
--------------------------- --------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position / status Non-Executive Director
--------------------------- --------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- --------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- --------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares of 5 pence each in Silence
the financial instrument, Therapeutics plc
type of instrument
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- --------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares in Silence
Therapeutics plc
--------------------------- --------------------------------------------
c) Prices(a) and volume(s) Price Volume
GBP4.0875 3,000
-------
--------------------------- --------------------------------------------
d) Aggregated information
- Aggregated volume 3,000 Ordinary Shares
- Price GBP12,262.50
--------------------------- --------------------------------------------
e) Date of the transaction 8 October 2020
--------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--------------------------- --------------------------------------------
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Dr. Giles Campion
--------------------------- --------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position / status Executive Director
--------------------------- --------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- --------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- --------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares of 5 pence each in Silence
the financial instrument, Therapeutics plc
type of instrument
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- --------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares in Silence
Therapeutics plc
--------------------------- --------------------------------------------
c) Prices(a) and volume(s) Price Volume
GBP4.04 4,945
-------
--------------------------- --------------------------------------------
d) Aggregated information
- Aggregated volume 4,945 Ordinary Shares
- Price GBP19,977.80
--------------------------- --------------------------------------------
e) Date of the transaction 9 October 2020
--------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--------------------------- --------------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208 Gem Hopkins, Head of IR & Corporate Communications Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20 Broker) 7597 5970 Daniel Adams/Gary Clarence European IR Tel: +44 (0) 20 Consilium Strategic Communications 3709 5700 Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com US IR Tel: +1 (443) 213-0505 Westwicke Partners Peter Vozzo peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing a C3 targeting programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBSBDGLSBDGGD
(END) Dow Jones Newswires
October 12, 2020 10:49 ET (14:49 GMT)
1 Year Silence Therapeutics Chart |
1 Month Silence Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
